353 related articles for article (PubMed ID: 37868743)
1. Emerging Therapeutic Potential of Cannabidiol (CBD) in Neurological Disorders: A Comprehensive Review.
Singh K; Bhushan B; Chanchal DK; Sharma SK; Rani K; Yadav MK; Porwal P; Kumar S; Sharma A; Virmani T; Kumar G; Noman AA
Behav Neurol; 2023; 2023():8825358. PubMed ID: 37868743
[TBL] [Abstract][Full Text] [Related]
2. Neuroprotection of Cannabidiol, Its Synthetic Derivatives and Combination Preparations against Microglia-Mediated Neuroinflammation in Neurological Disorders.
Yousaf M; Chang D; Liu Y; Liu T; Zhou X
Molecules; 2022 Aug; 27(15):. PubMed ID: 35956911
[TBL] [Abstract][Full Text] [Related]
3. Cannabis for the Treatment of Epilepsy: an Update.
Gaston TE; Szaflarski JP
Curr Neurol Neurosci Rep; 2018 Sep; 18(11):73. PubMed ID: 30194563
[TBL] [Abstract][Full Text] [Related]
4. An Overview of Cannabidiol as a Multifunctional Drug: Pharmacokinetics and Cellular Effects.
Martinez Naya N; Kelly J; Corna G; Golino M; Polizio AH; Abbate A; Toldo S; Mezzaroma E
Molecules; 2024 Jan; 29(2):. PubMed ID: 38257386
[TBL] [Abstract][Full Text] [Related]
5. Advances and Challenges of Cannabidiol as an Anti-Seizure Strategy: Preclinical Evidence.
Zavala-Tecuapetla C; Luna-Munguia H; López-Meraz ML; Cuellar-Herrera M
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555823
[TBL] [Abstract][Full Text] [Related]
6. Use of cannabidiol (CBD) for the treatment of cognitive impairment in psychiatric and neurological illness: A narrative review.
Ortiz R; Rueda S; Di Ciano P
Exp Clin Psychopharmacol; 2023 Oct; 31(5):978-988. PubMed ID: 37126037
[TBL] [Abstract][Full Text] [Related]
7. Modulation of Oxidative Stress and Neuroinflammation by Cannabidiol (CBD): Promising Targets for the Treatment of Alzheimer's Disease.
Hickey JP; Collins AE; Nelson ML; Chen H; Kalisch BE
Curr Issues Mol Biol; 2024 May; 46(5):4379-4402. PubMed ID: 38785534
[TBL] [Abstract][Full Text] [Related]
8. Cannabidiol and substance use disorder: Dream or reality.
Karimi-Haghighi S; Razavi Y; Iezzi D; Scheyer AF; Manzoni O; Haghparast A
Neuropharmacology; 2022 Apr; 207():108948. PubMed ID: 35032495
[TBL] [Abstract][Full Text] [Related]
9. Neuroprotective potential of cannabidiol: Molecular mechanisms and clinical implications.
Tambe SM; Mali S; Amin PD; Oliveira M
J Integr Med; 2023 May; 21(3):236-244. PubMed ID: 36973157
[TBL] [Abstract][Full Text] [Related]
10. Use of cannabidiol in the treatment of epilepsy.
Mazurkiewicz-Bełdzińska M; Zawadzka M
Neurol Neurochir Pol; 2022; 56(1):14-20. PubMed ID: 35211946
[TBL] [Abstract][Full Text] [Related]
11. Cannabidiol goes nuclear: The role of PPARγ.
Khosropoor S; Alavi MS; Etemad L; Roohbakhsh A
Phytomedicine; 2023 Jun; 114():154771. PubMed ID: 36965374
[TBL] [Abstract][Full Text] [Related]
12. Cannabidiol Adverse Effects and Toxicity.
Huestis MA; Solimini R; Pichini S; Pacifici R; Carlier J; Busardò FP
Curr Neuropharmacol; 2019; 17(10):974-989. PubMed ID: 31161980
[TBL] [Abstract][Full Text] [Related]
13. Cannabinoids as Immune System Modulators: Cannabidiol Potential Therapeutic Approaches and Limitations.
Aziz AI; Nguyen LC; Oumeslakht L; Bensussan A; Ben Mkaddem S
Cannabis Cannabinoid Res; 2023 Apr; 8(2):254-269. PubMed ID: 36413346
[No Abstract] [Full Text] [Related]
14. Cannabidiol and brain function: current knowledge and future perspectives.
Schouten M; Dalle S; Mantini D; Koppo K
Front Pharmacol; 2023; 14():1328885. PubMed ID: 38288087
[TBL] [Abstract][Full Text] [Related]
15. Cannabidiol in Neurological and Neoplastic Diseases: Latest Developments on the Molecular Mechanism of Action.
Ożarowski M; Karpiński TM; Zielińska A; Souto EB; Wielgus K
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33919010
[TBL] [Abstract][Full Text] [Related]
16. A scoping review on cannabidiol therapy in tuberous sclerosis: Current evidence and perspectives for future development.
Samanta D
Epilepsy Behav; 2022 Mar; 128():108577. PubMed ID: 35151190
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic applicability of cannabidiol and other phytocannabinoids in epilepsy, multiple sclerosis and Parkinson's disease and in comorbidity with psychiatric disorders.
de Fátima Dos Santos Sampaio M; de Paiva YB; Sampaio TB; Pereira MG; Coimbra NC
Basic Clin Pharmacol Toxicol; 2024 May; 134(5):574-601. PubMed ID: 38477419
[TBL] [Abstract][Full Text] [Related]
18. Overview of cannabidiol (CBD) and its analogues: Structures, biological activities, and neuroprotective mechanisms in epilepsy and Alzheimer's disease.
Li H; Liu Y; Tian D; Tian L; Ju X; Qi L; Wang Y; Liang C
Eur J Med Chem; 2020 Apr; 192():112163. PubMed ID: 32109623
[TBL] [Abstract][Full Text] [Related]
19. Effects of cannabidiol (CBD) in neuropsychiatric disorders: A review of pre-clinical and clinical findings.
Elsaid S; Kloiber S; Le Foll B
Prog Mol Biol Transl Sci; 2019; 167():25-75. PubMed ID: 31601406
[TBL] [Abstract][Full Text] [Related]
20. Molecular Targets of Cannabidiol in Neurological Disorders.
Ibeas Bih C; Chen T; Nunn AV; Bazelot M; Dallas M; Whalley BJ
Neurotherapeutics; 2015 Oct; 12(4):699-730. PubMed ID: 26264914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
